Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2028
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2028 Report Highlights:
The promising response of transdermal patches in the global market has further surged the further research and development in this sector. For instance in 2019, US FDA has approved Secuado, which is the first transdermal patch to treat Schizophrenia. Further in 2021, Gedeon Richter UK has announced that it has become marketing authorization holder (MAH) for Evra, a once weekly contraception for women of fertile age and the only transdermal contraceptive patch licensed in UK. The rising product launches in the global market will have a positive impact on the growth of market.
The pipeline for global transdermal patches is crowded, which suggests positive future of these patches in forthcoming years. For instance, recent clinical trial from Starton Therapeutics showed the promising results of STAR-LLD continuous delivery transdermal patch containing lenalidomide in a non-GLP rabbit pharmacokinetic (PK) and skin irritation study. Moreover, US FDA has also assigned a Prescription Drug User Fee Act target date of March 11, 2022 for the new drug application for Aldarity (donepezil transdermal system) for the treatment of patients with dementia due to mild, moderate, and severe Alzheimer disease. Aldarity is a once weekly transdermal formulation of donepezil that is designed to be worn for 7 days with consistent adhesion. These rising trends will propel the growth of market during the forecast period.
Currently, vaccine segment doesn’t have any transdermal patch showing that this area has lots of untapped opportunities for pharmaceutical companies. Several ongoing clinical trials are evaluating novel vaccine patch for influenza, HIV, COVID-19, and others. Recently in 2022, Institut Pasteur Korea (IPK) announced a research service agreement executed with Juvic Inc. for the joint development of microneedle based influenza vaccines. Merging Juvic’s microneedle production technology and IPK’s vaccine research and development capabilities, this collaboration is expected to facilitate the development of a microneedle influenza vaccine patch. Notably, the microneedle-based vaccine not only reduces the pain dramatically during vaccination but also can be distributed at room-temperature.
The global transdermal patch market is expected to witness high growth rates which is due to presence of key players and established healthcare infrastructure. Further beneficial government initiatives and an increase in the number of research partnerships are also expected to increase the market growth during the forecast period. Besides, high adoption rate of advance technologies is also expected to impel the growth of market in the region. As per our report findings, the global transdermal patch market is expected to surpass US$ 20 Billion by 2028.
US is currently dominating the global patch market due to presence of key transdermal drug delivery innovative companies and established healthcare infrastructure, beneficial government initiatives along with surge in the number of research partnership, increasing adoption of various strategies such as product innovation and increasing product launches and approval in this region. Apart from this, Europe has also emerged out to be potential market in last few years due to rising availability of products, increasing smoking population, and increasing awareness about the availability of patches in the market. The report global transdermal patch market provides detailed analysis on the currently market product along with their price, dosage, and generic availability. The insights into ongoing clinical trials by company, drug class, indication, and phase are also reported.
Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2028 Report Highlights:
- Research Methodology
- Global & Regional Transdermal Path Market Outlook
- Global Transdermal Patch Market Opportunity > USD 20 Billion
- Clinical Trials Insight By Company, Indication, Drug Molecule & Phase
- Comprehensive Insight On 60 Transdermal Patch Available Commercially
- Comprehensive Insight On 80 Transdermal Patch In Clinical Trials By Phase
- Transdermal Patch Dosage & Price Availability By Indication
- Competitive Landscape
The promising response of transdermal patches in the global market has further surged the further research and development in this sector. For instance in 2019, US FDA has approved Secuado, which is the first transdermal patch to treat Schizophrenia. Further in 2021, Gedeon Richter UK has announced that it has become marketing authorization holder (MAH) for Evra, a once weekly contraception for women of fertile age and the only transdermal contraceptive patch licensed in UK. The rising product launches in the global market will have a positive impact on the growth of market.
The pipeline for global transdermal patches is crowded, which suggests positive future of these patches in forthcoming years. For instance, recent clinical trial from Starton Therapeutics showed the promising results of STAR-LLD continuous delivery transdermal patch containing lenalidomide in a non-GLP rabbit pharmacokinetic (PK) and skin irritation study. Moreover, US FDA has also assigned a Prescription Drug User Fee Act target date of March 11, 2022 for the new drug application for Aldarity (donepezil transdermal system) for the treatment of patients with dementia due to mild, moderate, and severe Alzheimer disease. Aldarity is a once weekly transdermal formulation of donepezil that is designed to be worn for 7 days with consistent adhesion. These rising trends will propel the growth of market during the forecast period.
Currently, vaccine segment doesn’t have any transdermal patch showing that this area has lots of untapped opportunities for pharmaceutical companies. Several ongoing clinical trials are evaluating novel vaccine patch for influenza, HIV, COVID-19, and others. Recently in 2022, Institut Pasteur Korea (IPK) announced a research service agreement executed with Juvic Inc. for the joint development of microneedle based influenza vaccines. Merging Juvic’s microneedle production technology and IPK’s vaccine research and development capabilities, this collaboration is expected to facilitate the development of a microneedle influenza vaccine patch. Notably, the microneedle-based vaccine not only reduces the pain dramatically during vaccination but also can be distributed at room-temperature.
The global transdermal patch market is expected to witness high growth rates which is due to presence of key players and established healthcare infrastructure. Further beneficial government initiatives and an increase in the number of research partnerships are also expected to increase the market growth during the forecast period. Besides, high adoption rate of advance technologies is also expected to impel the growth of market in the region. As per our report findings, the global transdermal patch market is expected to surpass US$ 20 Billion by 2028.
US is currently dominating the global patch market due to presence of key transdermal drug delivery innovative companies and established healthcare infrastructure, beneficial government initiatives along with surge in the number of research partnership, increasing adoption of various strategies such as product innovation and increasing product launches and approval in this region. Apart from this, Europe has also emerged out to be potential market in last few years due to rising availability of products, increasing smoking population, and increasing awareness about the availability of patches in the market. The report global transdermal patch market provides detailed analysis on the currently market product along with their price, dosage, and generic availability. The insights into ongoing clinical trials by company, drug class, indication, and phase are also reported.
1. INTRODUCTION TO TRANSDERMAL PATCH
1.1 Overview of Transdermal Patch
1.2 Relevance of Transdermal Patch
2. TRANSDERMAL PATCHES CLASSIFICATION
2.1 Single/ Multiple-Layer Drug-in-Adhesive
2.2 Reservoir Transdermal Patches
2.3 Matrix Based Transdermal Patches
2.4 Vapor Patch
2.5 Active and Passive Patch
3. MECHANISM OF TRANSDERMAL PATCH DRUG DELIVERY
3.1 Properties of Transdermal Therapeutics
3.2 Components of Transdermal Patch
3.3 Mechanism of Motion Sickness, Nicotine & Female Contraceptive Transdermal Patch
3.4 Transdermal Patch v/s Traditional Drug Delivery Methods
4. GLOBAL TRANSDERMAL PATCH MARKET OUTLOOK
4.1 Current Market Scenario
4.2 Future Market Opportunity
5. GLOBAL TRANSDERMAL PATCH MARKET TRENDS BY REGION
5.1 US
5.2 Europe
5.3 China
5.4 Japan
5.5 South Korea
5.6 UK
6. TRANSDERMAL PATCHES FOR CARDIOVASCULAR DISEASES – MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
6.1 Nitro Glycerin Transdermal Patch
6.1.1 Nitro-Dur
6.1.2 Nitro TD Patch A
6.1.3 Generic Nitroglycerine Trandsdermal Patch
6.2 Clonidine Transdermal Patch (Catapres–TTS)
7. OPIOID DRUG CONTAINING TRANSDERMAL PATCHES - MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
7.1 Fentanyl Transdermal Patch
7.2 Buprenorphine Transdermal Patch
7.2.1 Butrans Patch
7.2.2 Bunov
8. TRANSDERMAL PATCH IN HORMONAL THERAPY - MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
8.1 Estradiol Transdermal Patch
8.1.1 Alora
8.1.2 Vivelle-Dot
8.1.3 Minivelle
8.1.4 Climara
8.1.5 Menostar
8.1.6 Femseven
8.1.7 Generic Estradiol Transdermal Patch
8.2 Testosterone Transdermal Patch (Androderm)
8.3 Estradiol & NorethindroneTransdermal Patch
8.3.1 Xulane/Ortho Evra
8.3.2 Combipatch
8.4 Estradiol/Levonorgestrel Transdermal Patch
8.5 Ethinyl Estradiol/Levonorgestrel (Twirla)
9. TRANSDERMAL PATCHES FOR NEUROLOGICAL DISORDERS - MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
9.1 Scopolamine Transdermal Patch (Transderm-Scop)
9.2 Selegiline Transdermal Patch (Emsam)
9.3 Methylphenidate Transdermal Patch (Daytrana)
9.4 Asenapine Transdermal Patch (Secuado)
9.5 Rivastigmine Transdermal Patch (Exelon)
9.6 Rotigotine Transdermal Patch (Neupro)
9.7 Ropinirole Hydrochloride (Haruropi Tape)
10. TRANSDERMAL PATCHES FOR OTHER CONDITIONS - MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
10.1 Nicotine Transdermal Patch (Nicoderm CQ/ Nicotinell TTS)
10.2 Oxybutynin Transdermal Patch (Oxytrol/Kentera)
10.3 Sancuso (Granisetron)
10.4 Methyl Salicate (Salonpas)
10.5 Bisono
11. GLOBAL TRANSDERMAL PATCH CLINICAL PIPELINE OVERVIEW
11.1 By Phase
11.2 By Region/Country
11.3 By Drug Class/Molecule
11.4 By Company
11.5 By Orphan & Fast Track Status
12. GLOBAL PATCH CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
12.1 Unknown
12.2 Research
12.3 Preclinical
12.4 Clinical
12.5 Phase-I
12.6 Phase-I/II
12.7 Phase-II
12.8 Phase-III
12.9 Preregistration
12.10 Registered
13. MARKETED TRANSDERMAL PATCH CLINICAL INSIGHT
14. GLOBAL TRANSDERMAL PATCH MARKET DYNAMICS
14.1 Favorable Market Parameters
14.2 Commercialization Challenges
15. GLOBAL TRANSDERMAL PATCH MARKET FUTURE OUTLOOK 2028
16. COMPETITIVE LANDSCAPE
16.1 3M Pharmaceuticals
16.2 Acrux
16.3 Agile Therapeutics
16.4 Allergan
16.5 ANI Pharmaceuticals
16.6 Antares Pharma
16.7 Bayer HealthCare Pharmaceuticals
16.8 Corium International
16.9 Chase Pharmaceuticals
16.10 DURECT Corporation
16.11 Endo Pharmaceuticals
16.12 Fempharm
16.13 Hisamitsu Pharmaceutical
16.14 Immune Pharmaceuticals
16.15 Imprimis Pharmaceuticals
16.16 Ipsen Bioscience
16.17 Johnson & Johnson
16.18 LaSalle Laboratories
16.19 Lavipharm-increase
16.20 Luye Pharma
16.21 MINRAD International
16.22 NeurogesX
16.23 Noven Pharmaceuticals
16.24 NuPathe
16.25 Nuvo Research
16.26 Novartis
16.27 Pain Therapeutics
16.28 ProStrakan
16.29 Purdue Pharma
16.30 Sanofi
16.31 Scilex Pharmaceuticals
16.32 Senju Pharmaceutical
16.33 Somerset Pharmaceuticals
16.34 Teikoku Seiyaku
16.35 Therapeutic Discovery Corporation
16.36 Transdermal Delivery Solutions Corp
16.37 UCB
16.38 Xel Pharmaceuticals
16.39 Zosano Pharma
1.1 Overview of Transdermal Patch
1.2 Relevance of Transdermal Patch
2. TRANSDERMAL PATCHES CLASSIFICATION
2.1 Single/ Multiple-Layer Drug-in-Adhesive
2.2 Reservoir Transdermal Patches
2.3 Matrix Based Transdermal Patches
2.4 Vapor Patch
2.5 Active and Passive Patch
3. MECHANISM OF TRANSDERMAL PATCH DRUG DELIVERY
3.1 Properties of Transdermal Therapeutics
3.2 Components of Transdermal Patch
3.3 Mechanism of Motion Sickness, Nicotine & Female Contraceptive Transdermal Patch
3.4 Transdermal Patch v/s Traditional Drug Delivery Methods
4. GLOBAL TRANSDERMAL PATCH MARKET OUTLOOK
4.1 Current Market Scenario
4.2 Future Market Opportunity
5. GLOBAL TRANSDERMAL PATCH MARKET TRENDS BY REGION
5.1 US
5.2 Europe
5.3 China
5.4 Japan
5.5 South Korea
5.6 UK
6. TRANSDERMAL PATCHES FOR CARDIOVASCULAR DISEASES – MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
6.1 Nitro Glycerin Transdermal Patch
6.1.1 Nitro-Dur
6.1.2 Nitro TD Patch A
6.1.3 Generic Nitroglycerine Trandsdermal Patch
6.2 Clonidine Transdermal Patch (Catapres–TTS)
7. OPIOID DRUG CONTAINING TRANSDERMAL PATCHES - MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
7.1 Fentanyl Transdermal Patch
7.2 Buprenorphine Transdermal Patch
7.2.1 Butrans Patch
7.2.2 Bunov
8. TRANSDERMAL PATCH IN HORMONAL THERAPY - MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
8.1 Estradiol Transdermal Patch
8.1.1 Alora
8.1.2 Vivelle-Dot
8.1.3 Minivelle
8.1.4 Climara
8.1.5 Menostar
8.1.6 Femseven
8.1.7 Generic Estradiol Transdermal Patch
8.2 Testosterone Transdermal Patch (Androderm)
8.3 Estradiol & NorethindroneTransdermal Patch
8.3.1 Xulane/Ortho Evra
8.3.2 Combipatch
8.4 Estradiol/Levonorgestrel Transdermal Patch
8.5 Ethinyl Estradiol/Levonorgestrel (Twirla)
9. TRANSDERMAL PATCHES FOR NEUROLOGICAL DISORDERS - MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
9.1 Scopolamine Transdermal Patch (Transderm-Scop)
9.2 Selegiline Transdermal Patch (Emsam)
9.3 Methylphenidate Transdermal Patch (Daytrana)
9.4 Asenapine Transdermal Patch (Secuado)
9.5 Rivastigmine Transdermal Patch (Exelon)
9.6 Rotigotine Transdermal Patch (Neupro)
9.7 Ropinirole Hydrochloride (Haruropi Tape)
10. TRANSDERMAL PATCHES FOR OTHER CONDITIONS - MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
10.1 Nicotine Transdermal Patch (Nicoderm CQ/ Nicotinell TTS)
10.2 Oxybutynin Transdermal Patch (Oxytrol/Kentera)
10.3 Sancuso (Granisetron)
10.4 Methyl Salicate (Salonpas)
10.5 Bisono
11. GLOBAL TRANSDERMAL PATCH CLINICAL PIPELINE OVERVIEW
11.1 By Phase
11.2 By Region/Country
11.3 By Drug Class/Molecule
11.4 By Company
11.5 By Orphan & Fast Track Status
12. GLOBAL PATCH CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
12.1 Unknown
12.2 Research
12.3 Preclinical
12.4 Clinical
12.5 Phase-I
12.6 Phase-I/II
12.7 Phase-II
12.8 Phase-III
12.9 Preregistration
12.10 Registered
13. MARKETED TRANSDERMAL PATCH CLINICAL INSIGHT
14. GLOBAL TRANSDERMAL PATCH MARKET DYNAMICS
14.1 Favorable Market Parameters
14.2 Commercialization Challenges
15. GLOBAL TRANSDERMAL PATCH MARKET FUTURE OUTLOOK 2028
16. COMPETITIVE LANDSCAPE
16.1 3M Pharmaceuticals
16.2 Acrux
16.3 Agile Therapeutics
16.4 Allergan
16.5 ANI Pharmaceuticals
16.6 Antares Pharma
16.7 Bayer HealthCare Pharmaceuticals
16.8 Corium International
16.9 Chase Pharmaceuticals
16.10 DURECT Corporation
16.11 Endo Pharmaceuticals
16.12 Fempharm
16.13 Hisamitsu Pharmaceutical
16.14 Immune Pharmaceuticals
16.15 Imprimis Pharmaceuticals
16.16 Ipsen Bioscience
16.17 Johnson & Johnson
16.18 LaSalle Laboratories
16.19 Lavipharm-increase
16.20 Luye Pharma
16.21 MINRAD International
16.22 NeurogesX
16.23 Noven Pharmaceuticals
16.24 NuPathe
16.25 Nuvo Research
16.26 Novartis
16.27 Pain Therapeutics
16.28 ProStrakan
16.29 Purdue Pharma
16.30 Sanofi
16.31 Scilex Pharmaceuticals
16.32 Senju Pharmaceutical
16.33 Somerset Pharmaceuticals
16.34 Teikoku Seiyaku
16.35 Therapeutic Discovery Corporation
16.36 Transdermal Delivery Solutions Corp
16.37 UCB
16.38 Xel Pharmaceuticals
16.39 Zosano Pharma
LIST OF FIGURES
Figure 1-1: Steps Involved in Transdermal Permeation
Figure 1-2: Ideal Properties of Transdermal Patch
Figure 2-1: Types of Commercially Available Transdermal Patch
Figure 3-1: Properties of Transdermal Therapeutics
Figure 3-2: Components of Transdermal Patch
Figure 3-3: Types of Permeation Enhancers
Figure 3-4: Schematic Representation of Iontophoresis
Figure 3-5: Mechanism of Scopolamine Transdermal Patch
Figure 3-6: Mechanism of Nicotine Transdermal Patch
Figure 3-7: Mechanism of Female Contraceptive Transdermal Patch
Figure 3-8: Issues with Traditional Drug Delivery Methods
Figure 3-9: Advantages of Transdermal Patch
Figure 3-10: Consistent Drug Supply by Transdermal Patch
Figure 4-1: Global – Transdermal Patch Market Size (US$ Billion), 2020 & 2021
Figure 4-2: Global – Transdermal Patch Market Share by Product (%), 2021
Figure 4-3: Global Transdermal Patch Market by Region (US$ Billion), 2021
Figure 4-4: Global Transdermal Patch Market by Region (%), 2021
Figure 4-5: Global Transdermal Patch Market by Region (US$ Billion), 2020
Figure 4-6: Global – Transdermal Patch Market (US$ Billion), 2022 - 2028
Figure 5-1: US vs. ROW – Transdermal Patch Market (US$ Billion), 2021
Figure 5-2: US vs. ROW – Transdermal Patch Market (US$ Billion), 2021
Figure 5-3: US – Transdermal Patch Market (US$ Billion), 2022 - 2028
Figure 5-4: Europe vs. ROW – Transdermal Patch Market (US$ Billion), 2021
Figure 5-5: Europe vs. ROW – Transdermal Patch Market (US$ Billion), 2021
Figure 5-6: Europe – Transdermal Patch Market (US$ Billion), 2022 - 2028
Figure 5-7: China vs. ROW – Transdermal Patch Market (US$ Billion), 2021
Figure 5-8: China vs. ROW – Transdermal Patch Market (US$ Billion), 2021
Figure 5-9: China – Transdermal Patch Market (US$ Billion), 2022 - 2028
Figure 5-10: Japan vs. ROW – Transdermal Patch Market (US$ Billion), 2021
Figure 5-11: Japan vs. ROW – Transdermal Patch Market (%), 2021
Figure 5-12: Japan – Transdermal Patch Market (US$ Billion), 2022 - 2028
Figure 5-13: South Korea – Transdermal Patch Market (US$ Billion), 2021 - 2028
Figure 5 -4: UK vs. ROW – Transdermal Patch Market (US$ Billion), 2021
Figure 5-15: UK vs. ROW – Transdermal Patch Market (%), 2021
Figure 5-16: UK – Transdermal Patch Market (US$ Billion), 2022 - 2028
Figure 6-1: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.1mg Film (US$), Feburary’2022
Figure 6-2: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.2mg Film (US$), Feburary’2022
Figure 6-3: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.3mg Film (US$), Feburary’2022
Figure 6-4: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.4mg Film (US$), Feburary’2022
Figure 6-5: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.6mg Film (US$), Feburary’2022
Figure 6-6: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.8mg Film (US$), Feburary’2022
Figure 6-7: Nitro-Dur – Per Unit Price of Transdermal patches by Strength (US$), Feburary’2022
Figure 6-8: Nitro TD Patch – Price for 30 Films Supply & Price Per Unit of 0.1mg Film (US$), Feburary’2022
Figure 6-9: Generic Nitroglycering Transdermal Patch – Price for 30 Films Supply & Price Per Unit of 0.1mg Film (US$), Feburary’2022
Figure 6-10: Generic Nitroglycering Transdermal Patch – Price for 30 Films Supply & Price Per Unit of 0.2mg Film (US$), Feburary’2022
Figure 6-11: Generic Nitroglycering Transdermal Patch – Price for 30 Films Supply & Price Per Unit of 0.4mg Film (US$), Feburary’2022
Figure 6-12: Generic Nitroglycering Transdermal Patch – Price for 30 Films Supply & Price Per Unit of 0.6 mg Film (US$), Feburary’2022
Figure 6-13: Catapres-TTS – FDA Approval & First Generic Approval Year
Figure 6-14: Catapres-TTS – Price for 4 Transdermal Film & Price Per Unit of 0.1mg Transdermal Film (US$), Feburary’2022
Figure 6-15: Catapres-TTS – Price for 4 Transdermal Film & Price Per Unit of 0.2mg Transdermal Film (US$), Feburary’2022
Figure 6-16: Catapres-TTS – Price for 4 Transdermal Film & Price Per Unit of 0.3mg Transdermal Film (US$), Feburary’2022
Figure 6-17: Generic Clonidine Patch – Price for 4 Transdermal Film & Price Per Unit of 0.1mg Transdermal Film (US$), Feburary’2022
Figure 6-18: Generic Clonidine Patch – Price for 4 Transdermal Film & Price Per Unit of 0.2mg Transdermal Film (US$), Feburary’2022
Figure 6-19: Generic Clonidine Patch – Price for 4 Transdermal Film & Price Per Unit of 0.3mg Transdermal Film (US$), Feburary’2022
Figure 6-20: Catapres-TTS – Recommended Initial & Incremented Dose (mg/Week)
Figure 6-21: Catapres-TTS – Monthly & Annual Treatment Cost using 0.1mg Dose (US$), February’2022
Figure 7-1: Duragesic – Approval Year by Region
Figure 7-2: Durogesic – Price for 5 Films Supply & Price Per Unit of 0.12mg Film (Euro/US$), Feburary’2022
Figure 7-3: Durogesic – Price for 5 Films Supply & Price Per Unit of 0.25mg Film (Euro/US$), Feburary’2022
Figure 7-4: US - Price for Per Unit Fentanyl Transdermal Patch Supply of Various Doses (US$), February’2022
Figure 7-5: US - Price for 5 Fentanyl Transdermal Patches Supply of Various Doses (US$), February’2022
Figure 7-6: Butrans – FDA Approval Year by Dose
Figure 7-7: US - Butrans FDA Approval & 1st Generic Approval Year
Figure 7-8: Butrans – Approval Year by Region
Figure 7-9: US - Price for 4 Butrans Patch Supply of 5mcg, 7.5mcg, 10mcg, 15mcg & 20mcg Transdermal Patches (US$), February’2022
Figure 7-10: US - Price per Unit of Butrans 5mcg, 7.5mcg, 10mcg, 15mcg & 20mcg Transdermal Patches (US$), February’2022
Figure 7-11: Butrans – Price for 4 Patches Supply & Price Per Unit of 10mg Patch (Euro/US$), Feburary’2022
Figure 7-12: Butrans – Price for 4 Patches Supply & Price Per Unit of 20mg Patch (Euro/US$), Feburary’2022
Figure 7-13: US - Price for 4 Buprenorphine Transdermal Patches supply of 5mcg, 7.5mcg, 10mcg, 15mcg & 20mcg Transdermal Patches (US$), February’2022
Figure 7-14: US – Per Unit Price for Buprenorphine Transdermal Patches supply of 5mcg, 7.5mcg, 10mcg, 15mcg & 20mcg Transdermal Patches (US$), February’2022
Figure 7-15: Butrans – Initial & Maximum Recommended Dose (mcg/hr)
Figure 7-16: Bunov – Price for 4 Patches Supply & Price Per Unit of 5mg Patch (Euro/US$), Feburary’2022
Figure 7-17: Bunov – Price for 4 Patches Supply & Price Per Unit of 10mg Patch (Euro/US$), Feburary’2022
Figure 7-18: Bunov – Price for 4 Patches Supply & Price Per Unit of 20mg Patch (Euro/US$), Feburary’2022
Figure 7-19: Bunov – Initial & Maximum Recommended Dose (mg/hr)
Figure 8-1: Alora – FDA Approval Year by Dose
Figure 8-2: Alora – Price for a Supply of 8 Patches of Dose 0.025mg, 0.05mg, 0.075mg & 0.1mg (US$), February’2022
Figure 8-3: Alora – Price per Unit of 0.025mg, 0.05mg, 0.075mg & 0.1mg Transdermal Patch(US$), February’2022
Figure 8-4: Alora – Recommended Dose for Treatment of vaginal Atrophy & Postmenopausal Osteoporosis (mg/Day Twice in a Week)
Figure 8-5: Vivelle-Dot – FDA Approval & First Generic Approval Year
Figure 8-6: Vivelle-Dot - Price for a Supply of 8 Patches of Dose 0.025mg, 0.0375mg, 0.05mg, 0.075mg & 0.1mg (US$), February’2022
Figure 8-7: Vivelle-Dot - Price per Unit of 0.025mg, 0.0375mg, 0.05mg, 0.075mg & 0.1mg Transdermal Patch (US$), February’2022
Figure 8-8: Recommended Dose for Treatment of vaginal Atrophy, vasomotor Symptoms, & Postmenopausal Osteoporosis (mg/Day Twice a Week)
Figure 8-9: Global – Vivelle Dot Annual Sales (US$/Yen Million), 2020 & 2021
Figure 8-10: Minivelle – FDA Approval Year by Dose
Figure 8-11: Minivelle – FDA Approval & First Generic Approval Year
Figure 8-12: US – Minivelle Patent Issue & Expiration Year
Figure 8-13: Minnivelle – Price for a Supply of 8 Patches & Price Per Unit of Various Doses (US$), February’2022
Figure 8-14: Minivelle - Recommended Dose by Indication (mg/Day), March’2021
Figure 8-15: Global – Minivelle Annual Sales (US$/Yen Million), 2020 & 2021
Figure 8-16: Climara – FDA Approval Year by Dose
Figure 8-17: Climara – FDA Approval & First Generic Approval Year
Figure 8-18: Climara – Average Price for a Supply of 4 Transdermal Films & Price Per Unit of Various Doses (US$), March’2021
Figure 8-19: Menostar – Price for 4 Films Supply & Price Per Unit of 0.14mcg Film (US$), Feburary’2022
Figure 8-20: Femseven – Price for 4 Patches Supply & Price Per Unit of 50mg Film (Euro/US$), Feburary’2022
Figure 8-21: Femseven – Price for 4 Patches Supply & Price Per Unit of 75mg Film (Euro/US$), Feburary’2022
Figure 8-22: Femseven – Price for 4 Patches Supply & Price Per Unit of 100mg Film (Euro/US$), Feburary’2022
Figure 8-23: Femseven – Initial & Increased Dosage for Postmenopausal Symptoms (mg/hr)
Figure 8-24: US – Price for 8 Estradiol Twice Weekly Patch Supply by Doses (US$), February’2022
Figure 8-25: US – Per Unit Price of Estradiol Twice Weekly Patch Supply by Doses (US$), February’2022
Figure 8-26: US – Price for 4 Estradiol Weekly Patch Supply by Doses (US$), February’2022
Figure 8-27: US – Per Unit Price of Estradiol Weekly Patch Supply by Doses (US$), February’2022
Figure 8-28: Androderm – Price for 60 Films Supply & per Unit Price of 2mg Transdermal Films (US$), February’2022
Figure 8-29: Androderm – Price for 30 patch Supply & per Unit Price of 4mg Transdermal Patch (US$), February’2022
Figure 8-30: Androderm – Recommended Initial & Maintainence Dose fot Treatment of Hypogonadism (mg/day)
Figure 8-31: Ortho Evra – FDA approval & Withdrawal Year
Figure 8-32: Xulane – FDA Approval & First Generic Approval Year
Figure 8-33: Ortho Evara – FDA & EMA Approval Year
Figure 8-34: Ethinyl Estradiol & Norelgestromin Patch – Price for a Supply of 3 Patches & Price Per Unit of 35mcg-150mcg Transdermal Patch (US$), Ferbuary’2022
Figure 8-35: Ethinyl Estradiol & Norelgestromin Patch – Recommended Schedule for Achieving Birth Control Effect (Days)
Figure 8-36: UK – Price for 3 Films Supply & Price Per Unit of Evra 33.9mg Film (Euro/US$), Feburary’2022
Figure 8-37: CombiPatch – Price for a Supply of 8 Patches & Price Per Unit of Various Doses (US$), February’2022
Figure 8-38: Global – Combipatch Annual Sales (US$/Yen Million), 2020 & 2021
Figure 8-39: Estradiol/Levonorgestrel – Approval Year by Region
Figure 8-40: Climara Pro – Price for a Supply of 4 Films & Price Per Unit of Transdermal Film (US$), February’2022
Figure 8-41: UK – Price for 12, 4 Patches Supply & Price Per Unit of Femseven Conti 50mg Film (Euro/US$), Feburary’2022
Figure 8-42: US - Twirla FDA Approval & Patent Exclusivity Year
Figure 8-43: US – Twirla Patent Issue & Expiration Year
Figure 8-44: Twirla – Price for a Supply of 3 Patches & Price Per Unit of 30mcg-120mcg Transdermal Patch (US$), February’2022
Figure 8-45: Twirla – Recommended Schedule for Achieving Birth Control Effect (Days)
Figure 9-1: Transderm-Scop – FDA Approval & 1st Generic Approval Year
Figure 9-2: Transderm-Scop - Price for 4 Patches Supply & Price Per Unit of 1mg Transdermal Patch (US$), February’2022
Figure 9-3: Transderm-Scop - Price for 10 Patches Supply & Price Per Unit of 1mg Transdermal Patch (US$), February’2022
Figure 9-4: Transderm-Scop - Price for 24 Patches Supply & Price Per Unit of 1mg Transdermal Patch (US$), February’2022
Figure 9-5: Scopolamine - Price for 4 Patches Supply & Price Per Unit of 1mg Transdermal Patch (US$), February’2022
Figure 9-6: Scopolamine - Price for 10 Patches Supply & Price Per Unit of 1mg Transdermal Patch (US$), February’2022
Figure 9-7: Scopolamine - Price for 24 Patches Supply & Price Per Unit of 1mg Transdermal Patch (US$), February’2022
Figure 9-8: Emsam - Price for 30 Patch Supply & Price Per Unit of Various Doses of Emsam Transdermal Patches (US$), February’2022
Figure 9-9: Emsam - Monthly & Annual Treatment Cost of Parkinson’s Disease (US$), February’2022
Figure 9-10: Daytrana – FDA Approval & Patent Exclusivity Year
Figure 9-11: US - Daytrana Patent Issue & Expiration Year
Figure 9-12: Daytrana - Price for 30 Transdermal Patch Supply of All Doses (US$), February’2022
Figure 9-13: Global – Vivelle Dot Annual Sales (US$/Yen Million), 2020 & 2021
Figure 9-14: US - Secuado Patent Issue & Expiration Year
Figure 9-15: Secuado – Price for 30 Transdermal Film & Price Per Unit of Various Dose Regimens (US$), February’2022
Figure 9-16: Secuado – Recommended Initial & Incremented Dose (mg/Day)
Figure 9-17: Exelon – Approval Year by Region
Figure 9-18: US – Exelon FDA Approval Year & 1st Generic Approval Year
Figure 9-19: US - Price for 30 Transdermal Patches & Per Unit Cost of Exelon Patch (US$), February’2022
Figure 9-20: UK – Price for 30 Films Supply & Price Per Unit of Exelone (Euro/US$), Feburary’2022
Figure 9-21: US - Price for 30 Transdermal Patches & Per Unit Cost of 4.6mg Rivastigmine Transdermal Patch (US$), February’2022
Figure 9-22: US - Price for 30 Transdermal Patches & Per Unit Cost of 9.5mg Rivastigmine Transdermal Patch (US$), February’2022
Figure 9-23: US - Price for 30 Transdermal Patches & Per Unit Cost of 13.3mg Rivastigmine Transdermal Patch (US$), February’2022
Figure 9-24: Exelon – Initial & Maintenance Dose for the Treatment of Parkinson’s disease
Figure 9-25: Exelon – Monthly & Annual Treatment Cost for Treatment of Parkinson’s disease (US$), February’2022
Figure 9-26: Neupro – Approval Year by Region
Figure 9-27: US - Neupro Approval Year by Indication
Figure 9-28: US – Aderis Pharma’s Neupro Patent Issue & Expiration Year
Figure 9-29: US – UCB’s Neupro Patent Issue & Expiration Year
Figure 9-30: US - Price for Supply of 30 Transdermal Films & Price Per Unit OF Neupro Patch (US$), February’2022
Figure 9-31: UK – Price for 28 Films Supply of Neupro Patch by Strength (Euro/US$), Feburary’2022
Figure 9-32: Neupro – Initial & Maximum Recommended Dose for Early Stage Parkinson (mg/day)
Figure 9-33: Neupro – Initial & Maximum Recommended Dose for Late Stage Parkinson (mg/day)
Figure 9-34: Neupro – Initial & Maximum Recommended Dose for Restless Leg Syndrome (mg/day)
Figure 9-35: Global – Neupro Half Year Sales (Euro/US$ Million), H1’2021 & H1’2020
Figure 9-36: Europe – Neupro Half Year Sales (Euro/US$ Million), H1’2021 & H1’2020
Figure 9-37: ROW – Neupro Half Year Sales (Euro/US$ Million), H1’2021 & H1’2020
Figure 9-38: Neupro - Half Year Sales by Region (Euro/US$ Million), H1’2021
Figure 9-39: Neupro - Half Year Sales by Region (%), H1’2021
Figure 9-40: Global – Neupro Annual Sales (Euro/US$ Million), 2018-2020
Figure 9-41: US – Neupro Annual Sales (Euro/US$ Million), 2018-2020
Figure 9-42: Europe – Neupro Annual Sales (Euro/US$ Million), 2018-2020
Figure 9-43: ROW – Neupro Annual Sales (Euro/US$ Million), 2018-2020
Figure 9-44: Japan – Per Unit Cost of Haruropi Tape Patch by Doses (Yen/US$), February’2022
Figure 9-45: Haruropi Tape – Initial & Maximum Recommended Dose (mg/day)
Figure 9-46: Global – Vivelle Dot Annual Sales (US$/Yen Million), 2020 & 2021
Figure 10-1: Nicotine Transdermal Patch – Approval Year by Region
Figure 10-2: Nicoderm CQ – Price for a Supply of 14 Transdermal Patches of Doses 7mg, 14mg & 21mg (US$), February’2022
Figure 10-3: Nicoderm CQ – Price per Unit of 7mg, 14mg & 21mg Transdermal Patch (US$), February’2022
Figure 10-4: UK – Price for 7 Films Supply of Nicotinell TTS Patch by Strength (Euro/US$), Feburary’2022
Figure 10-5: Generic Nicotine Patch – Price for a Supply of 7 Transdermal Patches of Doses 7mg, 14mg & 21mg (US$), February’2022
Figure 10-6: Generic Nicotine Patch – Price for a Supply of 14 Transdermal Patches of Doses 7mg, 14mg & 21mg (US$), March’2021
Figure 10-7: Generic Nicotine Patch – Price for a Supply of 28 Transdermal Patches of Doses 14mg & 21mg (US$), March’2021
Figure 10-8: Nicoderm CQ – Recommended Dose & Treatment Schedule for Patients with Consumption More Than 10 Cigarette/Days (mg/day)
Figure 10-9: Oxybutynin Transdermal Patch – Approval Year by Region
Figure 10-10: Oxytrol – Price of 8 Patch Supply & Price Per Unit of 3.9mg Transdermal Patch (US$), February’2022
Figure 10-11: Kentera – Price of 8 Patch Supply & Price Per Unit of 3.9mg Transdermal Patch (Euro/US$), February’2022
Figure 10-12: Sancuso – Approval Year by Region
Figure 10-13: US - Sancuso Patent Issue & Expiration Year
Figure 10-14: UK - Cost of Supply of Sancuso 3.1mg/24hours Patch (Euro/US$), February’2022
Figure 10-15: Sancuso – Cost of Supply of Patch by Region (US$), February’2022
Figure 10-16: Solanpras – Price of 9 Films Supply & Price Per Unit of Transdermal Patch (US$), February’2022
Figure 10-17: Bisono – Approval Year by Indication
Figure 10-18: Japan - Cost of Supply of Bisono Patch (JPY/US$), February’2022
Figure 10-19: Bisono – Initial & Maximum Recommended Dose (mg/hr)
Figure 11-1: Global – Transdermal Patch Pipeline by Phase (%), 2022 till 2028
Figure 11-2: Global – Transdermal Patch Pipeline by Phase (Number), 2022 till 2028
Figure 11-3: Global - Transdermal Patch Pipeline by Country (Number), 2022 till 2028
Figure 11-4: Global - Transdermal Patch Pipeline by Drug Class/Molecule (%), 2022 till 2028
Figure 11-5: Global - Transdermal Patch Pipeline by Company (%), 2019 till 2026
Figure 11-6: Global - Transdermal Patch Pipeline by Orphan & Fast Track Status (%), 2022 till 2028
Figure 14-1: Drivers for Transdermal Patch
Figure 14-2: Transdermal Patch Market Commercialization Challenges
Figure 1-1: Steps Involved in Transdermal Permeation
Figure 1-2: Ideal Properties of Transdermal Patch
Figure 2-1: Types of Commercially Available Transdermal Patch
Figure 3-1: Properties of Transdermal Therapeutics
Figure 3-2: Components of Transdermal Patch
Figure 3-3: Types of Permeation Enhancers
Figure 3-4: Schematic Representation of Iontophoresis
Figure 3-5: Mechanism of Scopolamine Transdermal Patch
Figure 3-6: Mechanism of Nicotine Transdermal Patch
Figure 3-7: Mechanism of Female Contraceptive Transdermal Patch
Figure 3-8: Issues with Traditional Drug Delivery Methods
Figure 3-9: Advantages of Transdermal Patch
Figure 3-10: Consistent Drug Supply by Transdermal Patch
Figure 4-1: Global – Transdermal Patch Market Size (US$ Billion), 2020 & 2021
Figure 4-2: Global – Transdermal Patch Market Share by Product (%), 2021
Figure 4-3: Global Transdermal Patch Market by Region (US$ Billion), 2021
Figure 4-4: Global Transdermal Patch Market by Region (%), 2021
Figure 4-5: Global Transdermal Patch Market by Region (US$ Billion), 2020
Figure 4-6: Global – Transdermal Patch Market (US$ Billion), 2022 - 2028
Figure 5-1: US vs. ROW – Transdermal Patch Market (US$ Billion), 2021
Figure 5-2: US vs. ROW – Transdermal Patch Market (US$ Billion), 2021
Figure 5-3: US – Transdermal Patch Market (US$ Billion), 2022 - 2028
Figure 5-4: Europe vs. ROW – Transdermal Patch Market (US$ Billion), 2021
Figure 5-5: Europe vs. ROW – Transdermal Patch Market (US$ Billion), 2021
Figure 5-6: Europe – Transdermal Patch Market (US$ Billion), 2022 - 2028
Figure 5-7: China vs. ROW – Transdermal Patch Market (US$ Billion), 2021
Figure 5-8: China vs. ROW – Transdermal Patch Market (US$ Billion), 2021
Figure 5-9: China – Transdermal Patch Market (US$ Billion), 2022 - 2028
Figure 5-10: Japan vs. ROW – Transdermal Patch Market (US$ Billion), 2021
Figure 5-11: Japan vs. ROW – Transdermal Patch Market (%), 2021
Figure 5-12: Japan – Transdermal Patch Market (US$ Billion), 2022 - 2028
Figure 5-13: South Korea – Transdermal Patch Market (US$ Billion), 2021 - 2028
Figure 5 -4: UK vs. ROW – Transdermal Patch Market (US$ Billion), 2021
Figure 5-15: UK vs. ROW – Transdermal Patch Market (%), 2021
Figure 5-16: UK – Transdermal Patch Market (US$ Billion), 2022 - 2028
Figure 6-1: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.1mg Film (US$), Feburary’2022
Figure 6-2: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.2mg Film (US$), Feburary’2022
Figure 6-3: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.3mg Film (US$), Feburary’2022
Figure 6-4: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.4mg Film (US$), Feburary’2022
Figure 6-5: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.6mg Film (US$), Feburary’2022
Figure 6-6: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.8mg Film (US$), Feburary’2022
Figure 6-7: Nitro-Dur – Per Unit Price of Transdermal patches by Strength (US$), Feburary’2022
Figure 6-8: Nitro TD Patch – Price for 30 Films Supply & Price Per Unit of 0.1mg Film (US$), Feburary’2022
Figure 6-9: Generic Nitroglycering Transdermal Patch – Price for 30 Films Supply & Price Per Unit of 0.1mg Film (US$), Feburary’2022
Figure 6-10: Generic Nitroglycering Transdermal Patch – Price for 30 Films Supply & Price Per Unit of 0.2mg Film (US$), Feburary’2022
Figure 6-11: Generic Nitroglycering Transdermal Patch – Price for 30 Films Supply & Price Per Unit of 0.4mg Film (US$), Feburary’2022
Figure 6-12: Generic Nitroglycering Transdermal Patch – Price for 30 Films Supply & Price Per Unit of 0.6 mg Film (US$), Feburary’2022
Figure 6-13: Catapres-TTS – FDA Approval & First Generic Approval Year
Figure 6-14: Catapres-TTS – Price for 4 Transdermal Film & Price Per Unit of 0.1mg Transdermal Film (US$), Feburary’2022
Figure 6-15: Catapres-TTS – Price for 4 Transdermal Film & Price Per Unit of 0.2mg Transdermal Film (US$), Feburary’2022
Figure 6-16: Catapres-TTS – Price for 4 Transdermal Film & Price Per Unit of 0.3mg Transdermal Film (US$), Feburary’2022
Figure 6-17: Generic Clonidine Patch – Price for 4 Transdermal Film & Price Per Unit of 0.1mg Transdermal Film (US$), Feburary’2022
Figure 6-18: Generic Clonidine Patch – Price for 4 Transdermal Film & Price Per Unit of 0.2mg Transdermal Film (US$), Feburary’2022
Figure 6-19: Generic Clonidine Patch – Price for 4 Transdermal Film & Price Per Unit of 0.3mg Transdermal Film (US$), Feburary’2022
Figure 6-20: Catapres-TTS – Recommended Initial & Incremented Dose (mg/Week)
Figure 6-21: Catapres-TTS – Monthly & Annual Treatment Cost using 0.1mg Dose (US$), February’2022
Figure 7-1: Duragesic – Approval Year by Region
Figure 7-2: Durogesic – Price for 5 Films Supply & Price Per Unit of 0.12mg Film (Euro/US$), Feburary’2022
Figure 7-3: Durogesic – Price for 5 Films Supply & Price Per Unit of 0.25mg Film (Euro/US$), Feburary’2022
Figure 7-4: US - Price for Per Unit Fentanyl Transdermal Patch Supply of Various Doses (US$), February’2022
Figure 7-5: US - Price for 5 Fentanyl Transdermal Patches Supply of Various Doses (US$), February’2022
Figure 7-6: Butrans – FDA Approval Year by Dose
Figure 7-7: US - Butrans FDA Approval & 1st Generic Approval Year
Figure 7-8: Butrans – Approval Year by Region
Figure 7-9: US - Price for 4 Butrans Patch Supply of 5mcg, 7.5mcg, 10mcg, 15mcg & 20mcg Transdermal Patches (US$), February’2022
Figure 7-10: US - Price per Unit of Butrans 5mcg, 7.5mcg, 10mcg, 15mcg & 20mcg Transdermal Patches (US$), February’2022
Figure 7-11: Butrans – Price for 4 Patches Supply & Price Per Unit of 10mg Patch (Euro/US$), Feburary’2022
Figure 7-12: Butrans – Price for 4 Patches Supply & Price Per Unit of 20mg Patch (Euro/US$), Feburary’2022
Figure 7-13: US - Price for 4 Buprenorphine Transdermal Patches supply of 5mcg, 7.5mcg, 10mcg, 15mcg & 20mcg Transdermal Patches (US$), February’2022
Figure 7-14: US – Per Unit Price for Buprenorphine Transdermal Patches supply of 5mcg, 7.5mcg, 10mcg, 15mcg & 20mcg Transdermal Patches (US$), February’2022
Figure 7-15: Butrans – Initial & Maximum Recommended Dose (mcg/hr)
Figure 7-16: Bunov – Price for 4 Patches Supply & Price Per Unit of 5mg Patch (Euro/US$), Feburary’2022
Figure 7-17: Bunov – Price for 4 Patches Supply & Price Per Unit of 10mg Patch (Euro/US$), Feburary’2022
Figure 7-18: Bunov – Price for 4 Patches Supply & Price Per Unit of 20mg Patch (Euro/US$), Feburary’2022
Figure 7-19: Bunov – Initial & Maximum Recommended Dose (mg/hr)
Figure 8-1: Alora – FDA Approval Year by Dose
Figure 8-2: Alora – Price for a Supply of 8 Patches of Dose 0.025mg, 0.05mg, 0.075mg & 0.1mg (US$), February’2022
Figure 8-3: Alora – Price per Unit of 0.025mg, 0.05mg, 0.075mg & 0.1mg Transdermal Patch(US$), February’2022
Figure 8-4: Alora – Recommended Dose for Treatment of vaginal Atrophy & Postmenopausal Osteoporosis (mg/Day Twice in a Week)
Figure 8-5: Vivelle-Dot – FDA Approval & First Generic Approval Year
Figure 8-6: Vivelle-Dot - Price for a Supply of 8 Patches of Dose 0.025mg, 0.0375mg, 0.05mg, 0.075mg & 0.1mg (US$), February’2022
Figure 8-7: Vivelle-Dot - Price per Unit of 0.025mg, 0.0375mg, 0.05mg, 0.075mg & 0.1mg Transdermal Patch (US$), February’2022
Figure 8-8: Recommended Dose for Treatment of vaginal Atrophy, vasomotor Symptoms, & Postmenopausal Osteoporosis (mg/Day Twice a Week)
Figure 8-9: Global – Vivelle Dot Annual Sales (US$/Yen Million), 2020 & 2021
Figure 8-10: Minivelle – FDA Approval Year by Dose
Figure 8-11: Minivelle – FDA Approval & First Generic Approval Year
Figure 8-12: US – Minivelle Patent Issue & Expiration Year
Figure 8-13: Minnivelle – Price for a Supply of 8 Patches & Price Per Unit of Various Doses (US$), February’2022
Figure 8-14: Minivelle - Recommended Dose by Indication (mg/Day), March’2021
Figure 8-15: Global – Minivelle Annual Sales (US$/Yen Million), 2020 & 2021
Figure 8-16: Climara – FDA Approval Year by Dose
Figure 8-17: Climara – FDA Approval & First Generic Approval Year
Figure 8-18: Climara – Average Price for a Supply of 4 Transdermal Films & Price Per Unit of Various Doses (US$), March’2021
Figure 8-19: Menostar – Price for 4 Films Supply & Price Per Unit of 0.14mcg Film (US$), Feburary’2022
Figure 8-20: Femseven – Price for 4 Patches Supply & Price Per Unit of 50mg Film (Euro/US$), Feburary’2022
Figure 8-21: Femseven – Price for 4 Patches Supply & Price Per Unit of 75mg Film (Euro/US$), Feburary’2022
Figure 8-22: Femseven – Price for 4 Patches Supply & Price Per Unit of 100mg Film (Euro/US$), Feburary’2022
Figure 8-23: Femseven – Initial & Increased Dosage for Postmenopausal Symptoms (mg/hr)
Figure 8-24: US – Price for 8 Estradiol Twice Weekly Patch Supply by Doses (US$), February’2022
Figure 8-25: US – Per Unit Price of Estradiol Twice Weekly Patch Supply by Doses (US$), February’2022
Figure 8-26: US – Price for 4 Estradiol Weekly Patch Supply by Doses (US$), February’2022
Figure 8-27: US – Per Unit Price of Estradiol Weekly Patch Supply by Doses (US$), February’2022
Figure 8-28: Androderm – Price for 60 Films Supply & per Unit Price of 2mg Transdermal Films (US$), February’2022
Figure 8-29: Androderm – Price for 30 patch Supply & per Unit Price of 4mg Transdermal Patch (US$), February’2022
Figure 8-30: Androderm – Recommended Initial & Maintainence Dose fot Treatment of Hypogonadism (mg/day)
Figure 8-31: Ortho Evra – FDA approval & Withdrawal Year
Figure 8-32: Xulane – FDA Approval & First Generic Approval Year
Figure 8-33: Ortho Evara – FDA & EMA Approval Year
Figure 8-34: Ethinyl Estradiol & Norelgestromin Patch – Price for a Supply of 3 Patches & Price Per Unit of 35mcg-150mcg Transdermal Patch (US$), Ferbuary’2022
Figure 8-35: Ethinyl Estradiol & Norelgestromin Patch – Recommended Schedule for Achieving Birth Control Effect (Days)
Figure 8-36: UK – Price for 3 Films Supply & Price Per Unit of Evra 33.9mg Film (Euro/US$), Feburary’2022
Figure 8-37: CombiPatch – Price for a Supply of 8 Patches & Price Per Unit of Various Doses (US$), February’2022
Figure 8-38: Global – Combipatch Annual Sales (US$/Yen Million), 2020 & 2021
Figure 8-39: Estradiol/Levonorgestrel – Approval Year by Region
Figure 8-40: Climara Pro – Price for a Supply of 4 Films & Price Per Unit of Transdermal Film (US$), February’2022
Figure 8-41: UK – Price for 12, 4 Patches Supply & Price Per Unit of Femseven Conti 50mg Film (Euro/US$), Feburary’2022
Figure 8-42: US - Twirla FDA Approval & Patent Exclusivity Year
Figure 8-43: US – Twirla Patent Issue & Expiration Year
Figure 8-44: Twirla – Price for a Supply of 3 Patches & Price Per Unit of 30mcg-120mcg Transdermal Patch (US$), February’2022
Figure 8-45: Twirla – Recommended Schedule for Achieving Birth Control Effect (Days)
Figure 9-1: Transderm-Scop – FDA Approval & 1st Generic Approval Year
Figure 9-2: Transderm-Scop - Price for 4 Patches Supply & Price Per Unit of 1mg Transdermal Patch (US$), February’2022
Figure 9-3: Transderm-Scop - Price for 10 Patches Supply & Price Per Unit of 1mg Transdermal Patch (US$), February’2022
Figure 9-4: Transderm-Scop - Price for 24 Patches Supply & Price Per Unit of 1mg Transdermal Patch (US$), February’2022
Figure 9-5: Scopolamine - Price for 4 Patches Supply & Price Per Unit of 1mg Transdermal Patch (US$), February’2022
Figure 9-6: Scopolamine - Price for 10 Patches Supply & Price Per Unit of 1mg Transdermal Patch (US$), February’2022
Figure 9-7: Scopolamine - Price for 24 Patches Supply & Price Per Unit of 1mg Transdermal Patch (US$), February’2022
Figure 9-8: Emsam - Price for 30 Patch Supply & Price Per Unit of Various Doses of Emsam Transdermal Patches (US$), February’2022
Figure 9-9: Emsam - Monthly & Annual Treatment Cost of Parkinson’s Disease (US$), February’2022
Figure 9-10: Daytrana – FDA Approval & Patent Exclusivity Year
Figure 9-11: US - Daytrana Patent Issue & Expiration Year
Figure 9-12: Daytrana - Price for 30 Transdermal Patch Supply of All Doses (US$), February’2022
Figure 9-13: Global – Vivelle Dot Annual Sales (US$/Yen Million), 2020 & 2021
Figure 9-14: US - Secuado Patent Issue & Expiration Year
Figure 9-15: Secuado – Price for 30 Transdermal Film & Price Per Unit of Various Dose Regimens (US$), February’2022
Figure 9-16: Secuado – Recommended Initial & Incremented Dose (mg/Day)
Figure 9-17: Exelon – Approval Year by Region
Figure 9-18: US – Exelon FDA Approval Year & 1st Generic Approval Year
Figure 9-19: US - Price for 30 Transdermal Patches & Per Unit Cost of Exelon Patch (US$), February’2022
Figure 9-20: UK – Price for 30 Films Supply & Price Per Unit of Exelone (Euro/US$), Feburary’2022
Figure 9-21: US - Price for 30 Transdermal Patches & Per Unit Cost of 4.6mg Rivastigmine Transdermal Patch (US$), February’2022
Figure 9-22: US - Price for 30 Transdermal Patches & Per Unit Cost of 9.5mg Rivastigmine Transdermal Patch (US$), February’2022
Figure 9-23: US - Price for 30 Transdermal Patches & Per Unit Cost of 13.3mg Rivastigmine Transdermal Patch (US$), February’2022
Figure 9-24: Exelon – Initial & Maintenance Dose for the Treatment of Parkinson’s disease
Figure 9-25: Exelon – Monthly & Annual Treatment Cost for Treatment of Parkinson’s disease (US$), February’2022
Figure 9-26: Neupro – Approval Year by Region
Figure 9-27: US - Neupro Approval Year by Indication
Figure 9-28: US – Aderis Pharma’s Neupro Patent Issue & Expiration Year
Figure 9-29: US – UCB’s Neupro Patent Issue & Expiration Year
Figure 9-30: US - Price for Supply of 30 Transdermal Films & Price Per Unit OF Neupro Patch (US$), February’2022
Figure 9-31: UK – Price for 28 Films Supply of Neupro Patch by Strength (Euro/US$), Feburary’2022
Figure 9-32: Neupro – Initial & Maximum Recommended Dose for Early Stage Parkinson (mg/day)
Figure 9-33: Neupro – Initial & Maximum Recommended Dose for Late Stage Parkinson (mg/day)
Figure 9-34: Neupro – Initial & Maximum Recommended Dose for Restless Leg Syndrome (mg/day)
Figure 9-35: Global – Neupro Half Year Sales (Euro/US$ Million), H1’2021 & H1’2020
Figure 9-36: Europe – Neupro Half Year Sales (Euro/US$ Million), H1’2021 & H1’2020
Figure 9-37: ROW – Neupro Half Year Sales (Euro/US$ Million), H1’2021 & H1’2020
Figure 9-38: Neupro - Half Year Sales by Region (Euro/US$ Million), H1’2021
Figure 9-39: Neupro - Half Year Sales by Region (%), H1’2021
Figure 9-40: Global – Neupro Annual Sales (Euro/US$ Million), 2018-2020
Figure 9-41: US – Neupro Annual Sales (Euro/US$ Million), 2018-2020
Figure 9-42: Europe – Neupro Annual Sales (Euro/US$ Million), 2018-2020
Figure 9-43: ROW – Neupro Annual Sales (Euro/US$ Million), 2018-2020
Figure 9-44: Japan – Per Unit Cost of Haruropi Tape Patch by Doses (Yen/US$), February’2022
Figure 9-45: Haruropi Tape – Initial & Maximum Recommended Dose (mg/day)
Figure 9-46: Global – Vivelle Dot Annual Sales (US$/Yen Million), 2020 & 2021
Figure 10-1: Nicotine Transdermal Patch – Approval Year by Region
Figure 10-2: Nicoderm CQ – Price for a Supply of 14 Transdermal Patches of Doses 7mg, 14mg & 21mg (US$), February’2022
Figure 10-3: Nicoderm CQ – Price per Unit of 7mg, 14mg & 21mg Transdermal Patch (US$), February’2022
Figure 10-4: UK – Price for 7 Films Supply of Nicotinell TTS Patch by Strength (Euro/US$), Feburary’2022
Figure 10-5: Generic Nicotine Patch – Price for a Supply of 7 Transdermal Patches of Doses 7mg, 14mg & 21mg (US$), February’2022
Figure 10-6: Generic Nicotine Patch – Price for a Supply of 14 Transdermal Patches of Doses 7mg, 14mg & 21mg (US$), March’2021
Figure 10-7: Generic Nicotine Patch – Price for a Supply of 28 Transdermal Patches of Doses 14mg & 21mg (US$), March’2021
Figure 10-8: Nicoderm CQ – Recommended Dose & Treatment Schedule for Patients with Consumption More Than 10 Cigarette/Days (mg/day)
Figure 10-9: Oxybutynin Transdermal Patch – Approval Year by Region
Figure 10-10: Oxytrol – Price of 8 Patch Supply & Price Per Unit of 3.9mg Transdermal Patch (US$), February’2022
Figure 10-11: Kentera – Price of 8 Patch Supply & Price Per Unit of 3.9mg Transdermal Patch (Euro/US$), February’2022
Figure 10-12: Sancuso – Approval Year by Region
Figure 10-13: US - Sancuso Patent Issue & Expiration Year
Figure 10-14: UK - Cost of Supply of Sancuso 3.1mg/24hours Patch (Euro/US$), February’2022
Figure 10-15: Sancuso – Cost of Supply of Patch by Region (US$), February’2022
Figure 10-16: Solanpras – Price of 9 Films Supply & Price Per Unit of Transdermal Patch (US$), February’2022
Figure 10-17: Bisono – Approval Year by Indication
Figure 10-18: Japan - Cost of Supply of Bisono Patch (JPY/US$), February’2022
Figure 10-19: Bisono – Initial & Maximum Recommended Dose (mg/hr)
Figure 11-1: Global – Transdermal Patch Pipeline by Phase (%), 2022 till 2028
Figure 11-2: Global – Transdermal Patch Pipeline by Phase (Number), 2022 till 2028
Figure 11-3: Global - Transdermal Patch Pipeline by Country (Number), 2022 till 2028
Figure 11-4: Global - Transdermal Patch Pipeline by Drug Class/Molecule (%), 2022 till 2028
Figure 11-5: Global - Transdermal Patch Pipeline by Company (%), 2019 till 2026
Figure 11-6: Global - Transdermal Patch Pipeline by Orphan & Fast Track Status (%), 2022 till 2028
Figure 14-1: Drivers for Transdermal Patch
Figure 14-2: Transdermal Patch Market Commercialization Challenges
